indicating substantial agreement between the measures. Conclusions: Our findings illustrate the difficulties in obtaining valid information on prenatal cannabis use. To improve the quality of cannabis use data, we suggest a 2-step approach starting with self-report.
Introduction
Cannabis is the most commonly used illicit substance in Western countries. In Europe, the 12-month prevalence of cannabis use among young adults increased from 5% in 1990 to 15% in 2005 [1] . In young Australian women, the 12-month prevalence of cannabis use was 24.4% [2] , and in young Canadian women it was 21.8% [3] . In pregnant women, the prevalence of cannabis use was much lower, i.e. in 2007, 2.9% of Dutch women and 1.8% of American women reported prenatal cannabis use [4, 5] .
In epidemiological studies, researchers often use different methods to assess substance use, such as biochemical measures and self-report. Biochemical measures provide clear information on recent substance use, yet are El Marroun/Tiemeier/Jaddoe/Hofman/ Verhulst/van den Brink/Huizink Eur Addict Res 2011; 17:37-43 38 restricted by error rates, brief detection time periods and high costs. Self-reports are less invasive and permit the evaluation of substance use over longer periods in time, but are influenced by possible reporter social desirability and forgetfulness. Although multiple studies on consistency and validity of multiple assessment methods among adults and adolescents have been reported [6] , little information is available on the agreement between self-reported cannabis use and urinalysis in pregnancy. Previous hospital-based research has demonstrated that self-reported use correlates moderately with biochemical measures of exposure to cannabis [7, 8] .
In previous studies of a population-based cohort in the Netherlands, we based prenatal cannabis use on self-reported information collected using a questionnaire in pregnancy [4, 9] . Although self-report is a commonly used measure to assess substance use, it is acknowledged that individuals may underreport or deny substance use, especially during pregnancy [10] . Cannabis use is not prosecuted in the Netherlands, and false negative reporting may therefore occur less frequently than in other countries; however, misclassification cannot be ruled out. Factors that may lead pregnant women to underreport substance use could be social desirability, forgetfulness, perceived norms about acceptability and fear of consequences. Therefore, it is important to verify self-reported information on prenatal cannabis use by means of detecting urinary cannabis metabolites. Moreover, we were particularly interested in exploring whether or not missing information on self-reported cannabis use was related to an increased risk of positive urine screens. In this study, the focus is on prenatal cannabis use exclusively, as in a general population-based cohort, the prevalence of other illicit drug use during pregnancy (e.g. cocaine, amphetamines) is expected to be very low. In addition, urinary detection time of other substances is shorter (e.g. cocaine assesses 1-3 days) as compared to detection time of the cannabis metabolite, which has a long half-life in the body of up to several days or even weeks, depending on the frequency of use [11] [12] [13] [14] [15] .
In the current study, self-reported information on prenatal cannabis use was compared to the presence of the metabolite 11-nor-⌬ 9-tetrahydrocannabinol-9-carboxylic acid (11-nor-⌬ 9-THC-9-COOH) using semiquantitative immunochemical urinalysis. Although available data suggest that self-reported cannabis use correlates only moderately with biochemical measures, we hypothesize substantial agreement between these measures in our cohort as cannabis use is not prosecuted in the Netherlands [16] .
Methods

Study Population
This study was conducted within the Generation R study, a population-based birth cohort in Rotterdam, the Netherlands [17] , set up to collect data on a sample of parents and their children from early pregnancy onwards. All children were born between April 2002 and January 2006 and constitute a prenatally enrolled birth cohort that is currently followed until young adulthood. In total 8,880 women (response rate 61%) were enrolled in Generation R during pregnancy. The study was conducted in accordance with the guidelines proposed in the World Medical Association Declaration of Helsinki, and it was approved by the Medical Ethics Committee of the Erasmus Medical Centre, Rotterdam. Written informed consent was obtained from all participants.
Self-Reported Maternal Substance Use
Alcohol, tobacco and cannabis use were measured using a selfreport questionnaire at enrolment (usually in the 1st trimester of pregnancy; response rate for report on cannabis use was 85.7%). These questionnaires were handled anonymously by using barcodes instead of names and birthdates. We explicitly asked them to retrospectively reply to 2 separate questions of whether they had used these substances before pregnancy, and whether they had used them in the last 3 months. In the latter question the response options were: 'no', 'yes, until I knew I was pregnant' and 'yes, I still use substances'. This information was therefore not specific for the entire gestational period. Mothers also provided information on the substance use of the biological father of the child. Based on these questions, we grouped the total population (n = 8,880) for this study in 4 nonoverlapping categories: (1) cannabis use before and during pregnancy (n = 220), (2) cannabis use before pregnancy only (n = 246), (3) missing information on cannabis use (n = 1,270) and (4) no cannabis use before or during pregnancy (n = 7,144). Self-reported numbers of cannabis use before pregnancy (2.8%) and during pregnancy (2.5%) were in agreement with national numbers of cannabis use among Dutch women aged between 15 and 64 years (recent use: 3.1%; current use: 1.5%) in the same period [18] . Substance use was unknown for 1,270 women of the total population (14.3%), which was due to failure to return the questionnaire (n = 764) or failure to fill out the specific question on substance use (n = 506).
Urine Collection and Analysis
Details of biological specimen collection and storage have been described previously [17] . Maternal urine samples were collected in early, mid-and late pregnancy between February 2004 and November 2005. From April to July 2008, about 14 batches (n = 300 per batch) of 3 ml of urine were sent to the Delta laboratory in Poortugaal, the Netherlands, and were tested on the presence of 11-nor-⌬ 9-THC-9-COOH using the DRI Cannabinoid Assay (Microgenics) with a cutoff value of 50 g/l as recommended by the manufacturer and the Substance Abuse and Mental Health Security Agency. Using lower cutoff levels (20-40 g/l) resulted in similar values of agreement between urinalyses and self-reports. We therefore only reported the results using the recommended cutoff level of 50 g/l. For each urine sample, creatinine concentrations were determined, as this provides information on possible urinary dilution (normal urine 6 1.8 mmol/l; diluted ! 1.8 mmol; inconsistent with human urine ^ 0.4 mmol/l) [19, 20] . Of all samples, 5.6% (n = 222) were diluted, and based on the creatinine levels only 1 sample was deemed as inconsistent with human urine. Deleting or including these samples in the analyses did not change any of the results. Urine samples were missing in almost half of the cohort because urine sample collection was performed during a limited period in the prenatal phase of the study [17] . For the current study, we could therefore use urine samples of 3,997 pregnant women. Due to this limited period of urine collection, 78.9% (n = 2,375) of the pregnant women filled out the questionnaire after urine collection, and the remaining 21.1% filled out the questionnaire before urine sample collection.
Data Analysis
First, we compared women with urine samples (n = 3,997) and women without urine samples (n = 4,883) on several characteristics such as maternal age, ethnicity [21] , educational level [22] , maternal psychopathology [23] and maternal report on alcohol, tobacco and cannabis use during pregnancy using independent t tests for continuous variables and a 2 test for categorical variables. The urinary average creatinine levels were compared using ANOVAs among the following groups: women reporting (1) cannabis use during pregnancy, (2) cannabis use before pregnancy, (3) no cannabis use and (4) women without information on cannabis use. Self-reported data on cannabis use and the presence of 11-nor-⌬ 9-THC-9-COOH in maternal urine were compared using a 2 ! 2 contingency table. We calculated the sensitivity and specificity for urinalyses compared to self-report, and vice versa, because we did not consider either of the 2 measurements as the golden standard.
Additionally, Yule's Y was calculated as a measure of overall agreement between self-reported cannabis use and urinalysis findings. Yule's ⌼ , also called the coefficient of colligation for dichotomous variables, is exactly equivalent to Hoehler's adjusted of agreement [24] , but appears to be less dependent on prevalence than . Yule's ⌼ is a symmetric measure taking on values between -1 and +1 implying a perfect negative or positive association -0 implies no association. Yule's Y is calculated using the 2 ! 2 table with: Y = ( Ί ad -Ί bc)/( Ί ad + Ί bc). Results were considered significant at p ! 0.01. We chose this conservative significance level because given a sufficiently large sample, as we have in this study, extremely small and negligible differences can be found to be statistically significant. Statistical analyses were performed using the Statistical Package of Social Sciences version 15.0 for Windows (SPSS Inc., Chicago, Ill., USA).
Results
Attrition Analysis
The urine samples of 3,997 of 8,880 pregnant mothers were available ( table 1 ) . Nonresponse analyses showed small differences between women with and without urine samples; women without urine samples were significantly younger (0.5 years), somewhat lower educated (39.4% higher educated vs. 45.5%) and smoked slightly more often during pregnancy (25.7 vs. 22.2%) as compared to women with urine samples. No statistically significant differences in maternal and paternal cannabis use, maternal alcohol use and ethnicity were found.
Self-Report and Urinalysis
Of 3,997 pregnant women, 92 reported having used cannabis during pregnancy (2.3%), while we found 71 positive urine screens of all women whether they reported cannabis use or not (1.8%). The numbers (92 self-reports and 71 positive urine screens) were not completely overlapping ( table 2 ) . Of the 92 mothers who reported having used cannabis during pregnancy, 33 mothers had a positive urine screen. Based on these data, the total number of women with at least some evidence of cannabis use during pregnancy amounts to 92 (self-reported) + 15 + 14 + 9 (positive urine tests without self-reported cannabis use) = 130, i.e. 3.3% of the group with urinalysis data ( table 2 , lower part). And, these data indicate that 92 of the 130 women with probable cannabis use during pregnancy (70.7%) reported their cannabis use. In addition, based on a combination of positive self-report and positive urinalysis data, at least 130 of the 3,997 pregnant women used cannabis during pregnancy (3.3%), i.e. 1.43 times the prevalence of cannabis use during pregnancy based on self-reported data only and 1.83 times the prevalence based on urinalysis data only. Table 2 (lower part) demonstrates that a sizeable proportion of positive urine screens was found in women who reported cannabis use during pregnancy (35.9%), a substantial proportion of positive screens was found in women who reported cannabis use only before pregnancy (7.6%), a very small proportion of positive screens was found in women who reported no cannabis use (0.4%), and an intermediate proportion of positive screens was found in women without self-report data on cannabis use (2.6%).
Creatinine Levels
Average creatinine levels were not statistically different across groups (F = 2.23, p = 0.082; table 2 ). Moreover, no significant difference between mean maternal urinary creatinine levels in women who reported having used cannabis during pregnancy (9. Gr oup B consists of 3 subgroups: B 1 , women reporting cannabis before pregnancy; B 2 , women without information on cannabis use; and B 3 , women reporting no cannabis use.
a Proportion of positive and negative urine screens based on the number of urine samples. b Proportion of urine samples based on the total number of participants.
Paternal Cannabis Use
Additional analyses showed that, compared to women that reported not using cannabis, among pregnant women that reported cannabis use, paternal cannabis use was more common (78.9 vs. 8.5%; p ! 0.001; phi = 0.38). Moreover, paternal cannabis use was also more common when maternal urine samples were positive (71.7 vs. 9.2%; p ! 0.001; phi = 0.26).
Discussion
In this study, we compared self-reported information on prenatal maternal cannabis use with the presence of the cannabis metabolite, 11-nor-9-THC-9-COOH, measured by semiquantitative immunochemical urinalysis. Our findings demonstrated that reliance on urinalysis of a single urine specimen underestimates the prevalence of cannabis use during pregnancy profoundly and may be biased toward long-term or heavy users, as they are more likely than occasional users to be detected through urinalysis. However, reliance on self-reported cannabis alone also underestimates the prevalence of prenatal cannabis use even in the Netherlands, where neither cannabis possession nor cannabis use is prosecuted.
Our findings are to some extent in agreement with other studies. First, our findings are consistent with the report by Shiono et al. [7] that only 43.2% of the women reporting cannabis also had a positive serum assay result. However, our findings were not fully consistent with the data of Markovic et al. [8] , who reported much higher proportions of positive urine screens (86.6%) in women reporting current cannabis use in early pregnancy. A plausible explanation for this finding is that this sample was not representative of the general population, but was a selected group of 570 (out of 1,347) pregnant women with a high prevalence of cannabis use during pregnancy measured by self-report (16.8%) and urinalysis (21.5%) [25] . Previous studies with different populations have reported moderate agreement between self-reports on cannabis use and urinalysis [6, 26] ; thus, we reported a higher agreement between self-report of cannabis use during pregnancy and urinalysis.
Sensitivity, of both self-report and urinalysis, was moderate, whereas specificity of both assessment procedures was high. If it can be assumed that false positive self-reports for cannabis use are unlikely, the negative urine screens of pregnant women reporting cannabis use during pregnancy are of interest. The main metabolite excreted in the urine (11-nor-⌬ 9-THC-9-COOH) is found within hours of exposure and remains detectable in the urine for 3-10 days after smoking a single dose. However, the length of time following cannabis use for a positive urine screen is dependent upon multiple factors, including the frequency and amount of cannabis, metabolic rate, excretion rate, half-life time, storage of the urine samples and the cannabis-user's age, body fat content, activity and diet [27, 28] . These difficulties may explain the finding of negative urine screens in 59 of the 92 women (64%) who reported cannabis use during pregnancy. A possible reason for this, and probably the main limitation of this study, is that we only took 1-3 urine samples per individual throughout pregnancy. Ideally, weekly urine sampling would provide better estimates and would provide information about newly used cannabis as well. So, in large epidemiological studies with limited numbers of urine samples, immunochemical urinalysis performed once per trimester cannot be regarded as the golden standard in assessing prenatal cannabis use. This may also mean that in the group of mothers who did not answer the question about substance use or reported nonuse, the true prevalence of cannabis use may be even higher. In fact, if the prevalence of prenatal cannabis use were estimated based on the urinalysis findings, the fact that at least two thirds of cannabis-using women were not detected in our study with urinalysis should be taken into account.
In addition, some other limitations in this study should be considered. First, extended frozen storage may have possibly led to degradation of cannabinoids over time, and may have led to an underestimation of the prevalence of cannabinoids in urine. However, several studies have shown that change in concentrations of 11-nor-⌬ 9-THC-9-COOH after long-term storage was not extensive ( ! 15%) [29, 30] . Second, we cannot rule out that women may wonder about specific aims for urine collection. We expected that knowing urine samples were collected (without a specific reason) did not influence cannabis use among these women. Third, exact information on the amount of time that had elapsed between filling out the questionnaire and urine collection was not available; however, in general women who visited the research center for anthropometrics, ultrasound measurements and blood and urine collection filled out the questionnaire at approximately the same time. Alternative detection methods such as hair examination is limited too, as cannabis incorporation depends on growth rate, anatomical region, age, gender, ethnicity, hair color and individual variability [31] . One could consider testing cannabis by using meconium, but meconium testing has some limita-tions as well. First, meconium begins forming in the 12th week of gestation, so this theoretically means collecting endogenous and exogenous wastes from the 2nd trimester onwards [32] . Therefore, in large populations with limited resources, the most sensible method is to use selfreported information on prenatal drug exposure, as this is likely to provide the best estimate for the lowest price (highest cost effectiveness). Fourth, the nonresponse analysis showed small differences between women with and without urine samples, which may increase the likelihood for cannabis use in women without urine samples. However, we previously reported that paternal cannabis use is the main determinant for prenatal cannabis use [4] , and in the current study, the additional analyses showed that paternal cannabis use occurs more often when mothers report cannabis use during pregnancy or when cannabinoids are detected in urine samples. Therefore, it is essential to consider paternal cannabis use. Finally, a total of 61% of all eligible women participated in the Generation R study [33] and they may not be completely representative of the general Rotterdam population [34] . This may perhaps have led to an unfavorable selection of nonusing women. Yet, this selection bias does not necessarily mean that the relationship between self-reported cannabis use and urinalysis presented in this study was distorted.
In conclusion, researchers and clinicians, should acknowledge that pregnant women may underreport current cannabis use, a situation that seems most prevalent in women admitting past cannabis use (i.e. cannabis use before the pregnancy) and in women refusing to provide information on prenatal cannabis use. Finally, our findings illustrate the difficulties in obtaining valid information on prenatal cannabis use. Nonetheless, selfreport seems to be an acceptable single method to determine cannabis use during pregnancy in epidemiological studies. Importantly, in order to improve the quality of cannabis use data, we suggest a 2-step approach starting with self-report information and followed by urinalysis in women who reported cannabis use before pregnancy, refused to answer questions about substance use during pregnancy and have partners that use cannabis.
